Processing

Please wait...

Settings

Settings

Goto Application

1. WO2021178534 - CDI ENHANCED COVID-19 TEST

Publication Number WO/2021/178534
Publication Date 10.09.2021
International Application No. PCT/US2021/020664
International Filing Date 03.03.2021
IPC
C12Q 1/70 2006.1
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
70involving virus or bacteriophage
CPC
C12Q 1/701
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms
70involving virus or bacteriophage
701Specific hybridization probes
C12Q 2600/158
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS
2600Oligonucleotides characterized by their use
158Expression markers
C12Q 2600/16
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS
2600Oligonucleotides characterized by their use
16Primer sets for multiplex assays
Applicants
  • HACKENSACK MERIDIAN HEALTH, INC. [US]/[US]
Inventors
  • ZHAO, Yanan
  • PERLIN, David, S.
  • PARK, Steven
Agents
  • D'ANTONIO, Alyssa, N.
  • KRUMHOLZ, Arnold, H.
  • DAVID, Sideny
  • LITTENBERG, Joseph, S.
  • MENTLIK, William, L.
Priority Data
17/100,28920.11.2020US
62/985,60205.03.2020US
62/989,96716.03.2020US
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) CDI ENHANCED COVID-19 TEST
(FR) TEST DE LA COVID-19 AMÉLIORÉ DU CDI
Abstract
(EN) A detection panel for the universal detection of SARS-like corona viruses and SARS-CoV-2 viruses and a method for using the detection panel are provided. The detection panel may be known as a Center for Discovery and Innovation ("CDI") detection panel (CDI Enhanced COVID-19 Test) and may also include an additional primer/probe set in the detection panel to detect the human RNase P gene (RP) in control samples and clinical specimens. The detection panel is designed for both universal detection of SARS-like coronaviruses using an E gene (envelope) detection assay, and specific detection of the SARS-CoV-2, using an N2 (nucleocapsid) detection assay.
(FR) L'invention concerne un panel de détection pour la détection universelle des coronavirus de type SARS et des virus SARS-CoV-2 et un procédé pour utiliser le panel de détection. Le panel de détection peut être connu sous le nom de panel de détection du centre pour la découverte et l'innovation ("Center for Discovery and Innovation" ("CDI")) (test COVID-19 amélioré du CDI) et peut également inclure un ensemble supplémentaire d'amorces/sondes dans le panel de détection pour détecter le gène de la RNase P humain (RP) dans des échantillons témoins et des spécimens cliniques. Le panel de détection est conçu à la fois pour la détection universelle des coronavirus de type SRAS à l'aide d'un test de détection (enveloppe) du gène E, et pour la détection spécifique du SARS-CoV-2, à l'aide d'un test de détection du N2 (de nucléocapside).
Related patent documents
Latest bibliographic data on file with the International Bureau